RVPH – reviva pharmaceuticals holdings, inc. (US:NASDAQ)
Stock Stats
News
Reviva Pharmaceuticals (NASDAQ:RVPH) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Reviva Pharmaceuticals (NASDAQ:RVPH) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $2.00 price target on the stock.
Reviva to Present Anti-Inflammatory Impacts of Brilaroxazine in Schizophrenia from the RECOVER 12-month Open Label Extension Trial at Neuroscience 2025
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis [Yahoo! Finance]
Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Fibrosis
Form ARS REVIVA PHARMACEUTICALS For: Dec 31
Form DEFA14A REVIVA PHARMACEUTICALS
Form DEF 14A REVIVA PHARMACEUTICALS For: Dec 18
Form PRE 14A REVIVA PHARMACEUTICALS For: Dec 18
Form 8-K REVIVA PHARMACEUTICALS For: Oct 14
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.